SuperworthTonix Pharmaceuticals EPS TNXP
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- −$12.94
- Latest quarter, Q2 FY26
- −$2.44
- Fiscal year 2025
- −$14.27
Tonix Pharmaceuticals' earnings per share was −$12.94 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.44.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$14.27 | n/a |
| FY2023 | −$21810.00 | n/a |
| FY2022 | −$54112.00 | n/a |
| FY2021 | −$26144.00 | n/a |
| FY2020 | −$80896.00 | n/a |
| FY2019 | −$3146752.00 | n/a |
| FY2018 | −$28292096.00 | n/a |
| FY2017 | −$34816000.00 | n/a |
| FY2016 | −$177766400.00 | n/a |
| FY2015 | −$293888000.00 | n/a |
| FY2014 | −$280576000.00 | n/a |
| FY2013 | −$357376000.00 | n/a |
| FY2012 | −$488448000.00 | n/a |
| FY2011 | −$327680000.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.44 | n/a | −$12.94 | |
| Q1 FY26 | −$2.93 | n/a | −$14.36 | |
| Q4 FY25 | −$3.98 | n/a | −$14.27 | |
| Q3 FY25 | −$3.59 | n/a | n/a | |
| Q2 FY25 | −$3.86 | n/a | n/a | |
| Q1 FY25 | −$2.84 | n/a | n/a | |
| Q3 FY24 | −$22.68 | n/a | −$5231.25 | |
| Q2 FY24 | −$1920.85 | n/a | −$9071.57 | |
| Q1 FY24 | −$535.72 | n/a | −$12073.72 | |
| Q4 FY23 | −$2752.00 | n/a | −$21810.00 | |
| Q3 FY23 | −$3863.00 | n/a | −$30002.00 | |
| Q2 FY23 | −$4923.00 | n/a | −$39707.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Tonix Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TNXPTonix Pharmaceuticals | −$12.94 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Tonix Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.